What is the therapeutic window for intravenous alteplase in acute ischemic stroke, and under what imaging criteria can it be extended beyond 4.5 hours?

Extended Window for Cerebral Stroke Thrombolysis

Intravenous alteplase can be administered up to 4.5 hours from symptom onset in carefully selected patients, but treatment beyond 4.5 hours is not recommended by current guidelines despite emerging imaging-based selection strategies. 1, 2

Standard Time Windows and Eligibility

0–3 Hour Window (Broadest Eligibility)

• All eligible patients should receive IV alteplase (0.9 mg/kg, maximum 90 mg) within 3 hours regardless of age >80 years, stroke severity (NIHSS >25), or use of antiplatelet therapy. 1, 3
• Treatment within 1.5 hours yields an odds ratio of 2.81 for favorable outcome versus placebo (95% CI 1.75–4.50). 3
• Each 15-minute delay reduces the probability of a favorable outcome—time is exponentially critical. 3

3–4.5 Hour Extended Window (ECASS III Criteria)

• Alteplase should be administered between 3 and 4.5 hours if patients meet ECASS III eligibility criteria, with an odds ratio of 1.40 for favorable outcome versus placebo (95% CI 1.05–1.85). 1, 3

• Four additional exclusion criteria apply in this window: 1

  • Age >80 years
  • Any oral anticoagulant use (regardless of INR)
  • NIHSS >25
  • Combined history of diabetes AND prior stroke

• The SITS-ISTR observational study of 664 patients treated at 3–4.5 hours showed comparable safety to the 0–3 hour window, with symptomatic ICH rates of 2.2% versus 1.6% (adjusted OR 1.32, p=0.052). 4

• Canadian registry data (CASES) demonstrated 39.4% of patients achieved mRS 0–1 at 90 days when treated at 3–4.5 hours, though there was a trend toward higher symptomatic ICH (7.8% vs 3.8%, p=0.06) and mortality (28.4% vs 21.4%, p=0.09) compared to earlier treatment. 5

Beyond 4.5 Hours: Current Evidence and Limitations

Guideline Position

• The American Heart Association/American Stroke Association gives a Class III: No Benefit recommendation against IV alteplase beyond 4.5 hours from last known well. 2
• This remains the definitive guideline position despite emerging research. 2

Imaging-Selected Patients (Investigational)

• In patients with unknown onset time selected by DWI-FLAIR mismatch, alteplase improved favorable outcomes (53.3% vs 41.8%; adjusted OR 1.61,95% CI 1.06–2.36) but was associated with higher parenchymal hemorrhage type 2 (4% vs 0.4%). 3
• A 2019 MRI-based trial (4.5–9 hours window) was stopped early for slow recruitment after enrolling only 119 patients and showed no significant benefit (OR 1.20,95% CI 0.63–2.27, p=0.58). 6
• A 2025 meta-analysis of extended window trials (>4.5 hours) showed improved excellent functional outcome (RR 1.24,95% CI 1.14–1.34) and good functional outcome (RR 1.18,95% CI 1.05–1.33), but with increased symptomatic ICH (RR 2.75,95% CI 1.49–5.05). 7

Ongoing Investigation

• The HOPE trial is investigating alteplase at 4.5–24 hours using CT perfusion criteria (ischemic core ≤70 mL, penumbra ≥10 mL, mismatch ≥20%), but results are pending. 8

Imaging Criteria for Extended Window Consideration

When considering treatment beyond 4.5 hours (off-guideline, ideally within a clinical trial): 3, 2

• DWI-FLAIR mismatch on MRI: Restricted diffusion on DWI with no corresponding FLAIR hyperintensity suggests stroke onset <4.5 hours ago. 3
• CT perfusion criteria (investigational): Ischemic core ≤70 mL, penumbra ≥10 mL, mismatch ratio ≥20%. 8
• These imaging approaches identify salvageable tissue but remain investigational and are not endorsed by current guidelines for routine clinical use beyond 4.5 hours. 2, 6

Mandatory Pre-Treatment Requirements (All Time Windows)

• Non-contrast CT or MRI must exclude intracranial hemorrhage before alteplase. 1, 3
• Blood pressure must be <185/110 mmHg before initiating alteplase and maintained <180/105 mmHg for 24 hours. 1, 3
• Bedside glucose must be >50 mg/dL (>2.7 mmol/L); this is the only mandatory laboratory test before treatment. 3

Dosing Protocol (All Time Windows)

• Total dose: 0.9 mg/kg (maximum 90 mg absolute). 3, 9
• Bolus: 10% of total dose (0.09 mg/kg) IV push over exactly 1 minute. 3, 9
• Infusion: Remaining 90% (0.81 mg/kg) continuous IV infusion over 60 minutes. 3, 9

Integration with Mechanical Thrombectomy

• Do not delay IV alteplase while obtaining vascular imaging or assessing thrombectomy eligibility. 3
• Administer IV alteplase even when the patient is being evaluated for or will undergo mechanical thrombectomy. 3
• Do not wait to assess the response to IV thrombolysis before proceeding to catheter angiography. 3
• For anterior circulation large-vessel occlusions presenting 6–24 hours after last known well, advanced imaging (CT perfusion or DW-MRI) determines thrombectomy eligibility using DAWN/DEFUSE-3 criteria. 3

Critical Pitfalls to Avoid

• Do not routinely treat patients beyond 4.5 hours outside of clinical trials or highly selected imaging-based protocols—this contradicts current guideline recommendations. 2
• Do not delay treatment within the 4.5-hour window to obtain advanced perfusion imaging; non-contrast CT is sufficient. 3
• Do not exclude patients >80 years old in the 0–3 hour window; age becomes an exclusion only in the 3–4.5 hour window. 1, 3
• Do not exclude patients with NIHSS >25 in the 0–3 hour window; severe stroke is not a contraindication when treated early. 3
• Recognize that later treatment windows carry progressively higher hemorrhagic risk—the Canadian registry showed a significant trend (p=0.013) for rising symptomatic ICH with later treatment. 5

Hemorrhagic Risk Across Time Windows

• Symptomatic intracranial hemorrhage occurs in 2.4–6.4% of patients treated with standard-dose alteplase within 4.5 hours. 3
• Extended window treatment (>4.5 hours) in imaging-selected patients shows higher symptomatic ICH rates (RR 2.75,95% CI 1.49–5.05) despite improved functional outcomes. 7
• The risk-benefit ratio fundamentally changes beyond 4.5 hours, with declining benefit and increasing hemorrhage risk. 2